PTAB Provides Guidance on Design Choice
Contributed by Ropes & Gray. Originally published on Patexia; republished here as part of the LexDana archive.
Informative Decisions Address Design Choice Considerations
Today, the Patent Trial & Appeal Board (PTAB) designated two ex parte appeal decision informative, Ex parte Spangler, Appeal No. 2018-003800 (Feb. 20, 2019) & Ex parte Maeda, Appeal No. 2010-009814 (Oct. 23, 2012)
The Spangler decision (here) affirmed an examiner’s obviousness rejection determining that claimed relative lengths and locations of two claimed components were a matter of obvious design choice. The Board explained that since the specification did not suggest that the relative lengths or locations were critical to the claimed invention, variations of such was a matter of design choice.
Showing the other side of the coin, Maeda (here) reversed the examiner’s obviousness rejection, which determined that the location of a claimed component of a manufacturing apparatus was a matter of obvious design choice because moving the component to the claimed location would result in a different function than shown in the prior art.
While helpful for patent prosecutors dealing with such rejections before the Examining Corps, the loose application of “design choice” arguments is also a common petitioner misstep in AIA Trial Proceedings.
Scott A. McKeown is an author of the Patents Post Grant
More insights
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…
Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026)
CASE OF THE WEEK Enanta Pharmaceuticals, Inc. v. Pfizer Inc., Appeal No. 2025-1427 (Fed. Cir. Jun. 23, 2026) In our Case of the Week, the Federal Circuit affirmed summary judgment invalidating all claims of Enanta’s Patent No. 11,358,953 as…